College of Medicine
Stacpoole Lab
Led by Peter W Stacpoole · Medicine
What we study
The lab studies mitochondrial diseases and new drug treatments, focusing on defects in the pyruvate dehydrogenase complex and testing drugs like dichloroacetate in clinical trials.
What working here is like
- Wet lab
- Clinical
- Human participants
- Project
- 1
- Papers
- 4
Current projects
Combined pharmacologic and AAV gene therapy of pyruvate dehydrogenase deficiency
Researching treatments for pyruvate dehydrogenase deficiency using drug therapy and gene therapy.
Summaries are written by AI in plain language from public symposium abstracts and may be imperfect.
Recent papers, explained
- A novel approach to reverse Warburg metabolism in patients with recurrent glioblastoma: A phase II pharmacodynamic study of dichloroacetate
2026 · Neuro-Oncology Advances
Evaluates whether dichloroacetate reduces lactate levels in brain tumors by restoring pyruvate dehydrogenase activity.
- Survival of pyruvate dehydrogenase complex deficiency (PDCD) patients treated with SL1009 (dichloroacete, DCA) matched to a published natural history cohort
2026 · Molecular Genetics and Metabolism
Show 2 more papersShow fewer
- Phase III trial of sodium dichloroacetate for pyruvate dehydrogenase complex deficiency in children
2026 · JCI Insight
Tests whether dichloroacetate improves motor function in children with a genetic disorder affecting the pyruvate dehydrogenase complex.
- Consensus Guidelines for Diagnosis and Management of Pyruvate Dehydrogenase Complex Deficiency
2026 · Journal of Inherited Metabolic Disease
Describes guidelines for diagnosing and treating a group of genetic disorders affecting the pyruvate dehydrogenase complex.
Plain-language summaries are AI-written and reviewed by us; check the paper for details.
How to reach out
Peter W Stacpoole hasn't set up this page yet. Their UF Scholars profile lists their publications.